Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NCT01824836 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT01824836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01824836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Not applicable
Overall status
Active, not recruiting
Start date
June 11, 2013
Completion date
December 31, 2026
Enrollment
1,046 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor-positive breast cancer, musculoskeletal complications, progesterone receptor-positive breast cancer, recurrent breast cancer, stage ia breast cancer, stage ib breast cancer, stage ii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer